Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

on to the webcast at least fifteen minutes prior to the scheduled start time.  A replay of this investor event will be available on the Nektar website approximately three hours after the presentation and will be archived for four weeks.

Figure A: Efficacy Table: Objective Tumor Response Rate by RECIST (Investigator Assessment)Response by RECIST v 1.0

NKTR-102

145 mg/m²

q14d

ITT/Evaluable

NKTR-102

145 mg/m²

q21d ITT/EvaluableTOTAL

ITT/EvaluableN

35/31*

35

70/66ORR (confirmed + unconfirmed

11 (31%)/11 (35%)

11 (31%)

22 (31%)/22 (33%)ORR (confirmed)

10 (29%)/10 (32%)

9 (26%)

19 (27%)/19 (29%)CR (confirmed)

2 (6%)/2 (7%)

0

2 (3%)/2 (3%)PR (confirmed)

8 (23%)/8 (26%)

9 (26%)

17 (24%)/17 (26%)SD

17 (48%)/13 (42%)

17 (48%)

34 (49%)/30 (45%)PD

8 (23%)/8 (26%)

9 (26%)

17 (24%)/17 (26%)Clinical benefit

(CR+PR+SD greater than or equal to 6 months)

12 (34%)/12 (39%)

15 (43%)

27 (38%)/27 (41%)*4 patients in the Q14 day arm with no post-baseline scans, but no evidence of progression were excluded from analysis in the evaluable population.Figure B: Efficacy Table: Response rate by prior therapyPrior Therapy Subgroup

Response by RECIST v 1.0

Evaluable PatientsNKTR-102

145 mg/m²

q14d

N=31

NKTR-102

145 mg/m²

q21d

N=35TOTALPrior A/T only

ORR (confirmed)

7/22 (32%) 5/21 (24%)12/43 (28%)Prior A/T in MBC

ORR (confirmed)

2/6 (33%)

2/8 (25%)

4/14 (29%)Prior A/T/C

ORR (confirmed)

2/6 (33%)

3/9 (33%)5/15 (33%)Figure C: Efficacy Table: Response rate by tumor characteristicsDisease Subgroup

Response by RECIST v 1.0

Evaluable PatientsNKTR-102

145 mg/m²

q14d

N=31

<
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014  The management team at ... will hold a conference call on July 31, ... quarter ended June 30, 2014.  The call details ... , 8:30 am EDTDial-in numbers: , Toll free: ... 317-0790Webcast (live & archive): , www.columbialabs.com , ...
(Date:7/23/2014)... , July 23, 2014 ... business that is facing currency headwinds, increased price competition ... CEO Sir Andrew Witty points out that ... the development pipeline as reason to be confident about long-term ... drive long-term growth. CFO Simon Dingemans ...
(Date:7/23/2014)... DUBLIN , July 23, 2014 ... addition of the "Prepackaged Medical Kits and ... to their offering. ... worldwide markets for Prepackaged Medical Kits and Trays ... ENT Custom Trays, Ophthalmic Custom Trays, Custom Basin ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report 2
... April 21 BioMarin Pharmaceutical Inc. (Nasdaq: ... 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), ... Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. ... the first half of 2010. "We plan to ...
... studies; Data to be presented at AACR - ... and development company Esperance Pharmaceuticals today presented positive ... support the initiation of clinical trials in cancer. ... Cationic Lytic Peptide (CLYP(TM)) platform technology. EP-100 is ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 2BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 3BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 4First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 2First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 3
(Date:7/23/2014)... 2014 Inventor and entrepreneur Delegate Joe ... to the gas pump – sharing his passion for ... 30 at Noon. , With 24 patents granted and ... than anyone in the General Assembly since Thomas Jefferson. ... yard marker as seen on television, an instrument for ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Regularly checking the pulse ... researchers report. "Screening pulse is the method of ... age 65 who have never had a stroke. Our ... and easy way to identify people who might need ... study author Dr. Bernd Kallmunzer, of Erlangen University in ...
(Date:7/23/2014)... Northwest Agricultural and Forestry University in Shaanxi province, and ... of agreement that lays the groundwork for establishing the ... , The signing ceremony was held in the city ... of the U.S. Department of Agriculture and China,s Ministry ... landmark event for UC Davis and for our World ...
(Date:7/23/2014)... Rich Dad® Education, a leader in financial education, is ... to support Habit for Humanity of Lee and Hendry Counties. ... be donated to Habitat for Humanity. Additionally, all the items ... Habitat for Humanity ReStore thrift store located at 31 Willis ... the highlights of the yard sale was a visit from ...
(Date:7/23/2014)... July 23, 2014 Global Cardio Care, ... Enhanced External Counterpulsation (EECP), is celebrating the 100th ... therapy at the health center. , Weber has ... Since receiving ongoing EECP therapy since 1999, he no ... Soulati, CEO of Global Cardio Care, introduced the ...
Breaking Medicine News(10 mins):Health News:Celebrating Innovation and Invention 2Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2
... study researchers say Cocoa flavonols, shown// to benefit heart health, ... were found to increase blood flow to key areas of ... young women, researcher tested the brain’s activation during cognitive tasks ... flavonol-rich CocoaVia drink made by Mars once a day for ...
... tobacco smoke causes genetic damage// in the developing fetus, ... that smoking during pregnancy causes genetic damage in the ... ,Stephen G. Grant, Ph.D., associate professor of environmental and ... of Public Health re-examined data from the earlier study ...
... Elderly women, especially those above the age of 80yrs, ... their condition may remain undetected for long as well. ... of JAMA, said that about 75% of the participants ... have hypertension. ,The research, which was based on ...
... patients who don't respond well to conventional// therapy may ... portal www.eurekalert.org. ,Richard Fedorak, a professor of gastroenterology ... University of Bologna in Italy and the University of ... six-week period to 30 patients aged 18-65. ...
... Researchers have found that Leishmania parasite utilizes mannose for ... requires glucose. ,Associate Professor Malcolm McConville and ... of Melbourne have found a break thorough to control ... Leishmania is found to utilize sugar mannose in the ...
... The tempting red color of strawberries may be the culprit ... popular summer fruit, Swedish researchers say., ,"The allergen is ... but it is not clear exactly how. We need to ... ,Alm was quoted in the magazine Chemistry World, the publication ...
Cached Medicine News:Health News:Elderly Women Remain At Risk From Hypertension 2Health News:Metabolism cycle of Kala-Azar parasite revealed 2
Thermal Cautery, Reusable Base Unit. Burns at approximately 1200C (2200 F), non-sterile base unit with 1 non-sterile tip, 1 set single-use batteries. The two (2) AA batteries are replaceable (alkalin...
... The 2200 is ideal for applications ... of heat. , ,The autoclavable handpiece with ... thermal cautery electrodes, allowing the physician to ... variety of procedures., ,The 2200 includes the ...
... The 2201 is ideal for ... accurate application of heat. , ,The ... an assortment of reusable thermal cautery ... the flexibility to perform a wide ...
No Scalpel Vasectomy Ring Clamp, 5 1/2" (14cm), gold finger rings...
Medicine Products: